Differential Healing After Sirolimus, Paclitaxel and Bare Metal Stent Placement in Combination with PPARγ Agonists: Requirement for mTOR/Akt2 in PPARγ Activation

RATIONALE: Sirolimus- (SES) and paclitaxel-eluting coronary stents (PES) are used to reduce restenosis, but have different sites of action. The molecular targets of sirolimus (SRL) overlap with those of the PPARγ agonist, rosiglitazone (RSG), but the consequence of this interaction on endothelializa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circ Res
Hauptverfasser: Finn, Aloke V., John, Michael, Nakazawa, Gaku, Polavarapu, Rohini, Karmali, Vinit, Xu, Xin, Cheng, Qi, Davis, Talina, Raghunathan, Chitra, Acampado, Eduardo, Ezell, Tucker, Lajoie, Scott, Eppihimer, Michael, Kolodgie, Frank D., Virmani, Renu, Gold, Herman Kalman
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2009
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492118/
https://ncbi.nlm.nih.gov/pubmed/19797172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.109.200519
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge